Will Regenxbio Inc (RGNX) Go Down Anytime Soon?

September 17, 2017 - By Stephen Andrade

The stock of Regenxbio Inc (NASDAQ:RGNX) is a huge mover today! The stock increased 5.21% or $1.4 on September 15, reaching $28.25. About 801,458 shares traded or 206.46% up from the average. Regenxbio Inc (NASDAQ:RGNX) has risen 51.43% since September 17, 2016 and is uptrending. It has outperformed by 34.73% the S&P500.
The move comes after 7 months positive chart setup for the $872.77M company. It was reported on Sep, 17 by Barchart.com. We have $29.95 PT which if reached, will make NASDAQ:RGNX worth $52.37M more.

Analysts await Regenxbio Inc (NASDAQ:RGNX) to report earnings on November, 8. They expect $-0.74 EPS, down 7.25 % or $0.05 from last year’s $-0.69 per share. After $-0.47 actual EPS reported by Regenxbio Inc for the previous quarter, Wall Street now forecasts 57.45 % negative EPS growth.

Regenxbio Inc (NASDAQ:RGNX) Ratings Coverage

Among 4 analysts covering Regenxbio (NASDAQ:RGNX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Regenxbio had 4 analyst reports since October 12, 2015 according to SRatingsIntel. The company was initiated on Monday, October 12 by Piper Jaffray. As per Monday, October 12, the company rating was initiated by Bank of America. On Tuesday, October 13 the stock rating was initiated by Morgan Stanley with “Overweight”. The firm earned “Buy” rating on Tuesday, October 20 by Chardan Capital Markets.

More important recent Regenxbio Inc (NASDAQ:RGNX) news were published by: Bizjournals.com which released: “Rockville biotech buys Cambridge gene therapy firm for $86M” on August 25, 2017, also Streetinsider.com published article titled: “Regenxbio Inc. (RGNX) PT Raised to $75 at Chardan Capital Markets”, Globenewswire.com published: “REGENXBIO to Present at Upcoming Investor Conferences” on August 31, 2017. More interesting news about Regenxbio Inc (NASDAQ:RGNX) was released by: Streetinsider.com and their article: “Form 425 Dimension Therapeutics, Filed by: REGENXBIO Inc.” with publication date: September 01, 2017.

REGENXBIO Inc. is a clinical-stage biotechnology company. The company has market cap of $872.77 million. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. It currently has negative earnings. The Firm develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.